M9140
Phase 1Small molecule
EMD Serono Research & Development Institute, Inc.M9140 is one of 88 small molecule programs targeting Colorectal Cancer. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
348 competitors in Solid Tumor
#DrugCompanyPhaseTrials
1Fludara
SanofiPreclinical
DATROWAY
Daiichi SankyoPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Navmi
SSummit Therapeutics
Preclinical
Paxil
SSebela Pharmaceuticals Development LLC
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Ifinatamab Deruxtecan
Daiichi SankyoPreclinical
Tulmimetostat
NovartisPreclinical
Carboplatin AUC-5
Merck & Co.Preclinical
MHB036C
MMinghui Pharmaceutical (Hangzhou) Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Solid Tumor2 trials
PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)
Active, not recruiting·EMD Serono Research & Development Institute, Inc.·Preclinical·NCT06710132·184 enrolled
EMD Serono Research & Development Institute, Inc.·Preclinical·NCT06710132·184 enrolledColorectal Cancer1 trial
A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)
Active, not recruiting·EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05464030·220 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05464030·220 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for M9140. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details